Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28965986 | 0.86 | SLC40A1 (0.44) | ABCC9ABCC8KCNJ11KCNJ8NAMPT | |
| SCHEMBL329369 | 0.82 | — | — | |
| SCHEMBL9097096 | 0.81 | POLB (0.50) | ABCC9ABCC8KCNJ11KCNJ8NAMPT | |
| SCHEMBL41731 | 0.80 | — | — | |
| SCHEMBL7826145 | 0.80 | — | — | |
| SCHEMBL16708 | 0.80 | — | — | |
| SCHEMBL329370 | 0.80 | — | — | |
| SCHEMBL1260157 | 0.80 | — | — | |
| SCHEMBL30817869 | 0.80 | — | — | |
| SCHEMBL4732573 | 0.78 | ABCC9 (0.45) | ABCC9ABCC8KCNJ11KCNJ8NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990431-B1 | NANOMODIFIED BACKBONES FOR POLYIMIDES WITH DIFUNCTIONAL AND MIXED-FUNCTIONALITY ENDCAPS | BOEING CO (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4332169-A2 | NANOMODIFIED BACKBONES FOR POLYIMIDES WITH DIFUNCTIONAL AND MIXED-FUNCTIONALITY ENDCAPS | The Boeing Company (US) | 2024-03-06 | — | — | EP | claimed |
| CN-113559264-A | Methods of treating microbial infections including mastitis | 罗达制药公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113144197-A | Method of treating topical microbial infections | 罗达制药公司 | 2021-07-23 | — | — | CN | claimed |
| CN-110845436-A | Thiazolesulfone compound and preparation and application thereof | 合肥锦绣田园化工科技有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-110204716-A | Polyimide oligomers and resin system | 波音公司 | 2019-09-06 | — | — | CN | claimed |
| CN-105384932-B | Nano-modified backbone of polyimides with difunctional and mixed-functional endcaps | 波音公司 | 2019-06-04 | — | — | CN | claimed |
| US-9670325-B2 | Nanomodified backbones for polyimides with difunctional and mixed-functionality endcaps | THE BOEING COMPANY (US) | 2017-06-06 | — | — | US | claimed |
| US-9505864-B2 | Nanomodified backbones for polyimides with difunctional and mixed-functionality endcaps | THE BOEING COMPANY (US) | 2016-11-29 | — | — | US | claimed |
| US-20160208053-A1 | NANOMODIFIED BACKBONES FOR POLYIMIDES WITH DIFUNCTIONAL AND MIXED-FUNCTIONALITY ENDCAPS | THE BOEING COMPANY | 2016-07-21 | — | — | US | claimed |
| CN-102307933-A | Oligomers with diphenylethynyl endcaps | BOEING CO | 2012-01-04 | — | — | CN | claimed |
| US-8063168-B2 | Oligomers with di-phenylethynyl endcaps | THE BOEING COMPANY (US) | 2011-11-22 | — | — | US | claimed |
| WO-2010141106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY (US) | 2010-12-09 | — | — | WO | claimed |
| US-20100204412-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY | 2010-08-12 | — | — | US | claimed |
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | THE BOEING COMPANY | 2010-08-12 | — | — | US | claimed |
| CN-1433396-A | Pharmaceutical compounds | NICOX SA (FR) | 2003-07-30 | — | — | CN | claimed |
| US-6569954-B1 | Interpenetrating polymer networks | THE BOEING COMPANY | 2003-05-27 | — | — | US | claimed |
| CN-1358178-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-10 | — | — | CN | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| US-5645925-A | POLYMER BLEND | BOEING COMPANY (US) | 1997-07-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | AADAC, ACMSD, ECPAS | ABCC9 1793/4885ABCC8 2522/4885KCNJ11 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.